MedPath

Study of Ayurvedic formulation in Diabetic Kidney Disease.

Phase 3
Completed
Conditions
Health Condition 1: null- k/c/o/ Diabetic Kidney Disease. 3months k/c/o Type 2 DM at least since 6 months.Health Condition 2: E112- Type 2 diabetes mellitus with kidney complicationsHealth Condition 3: E112- Type 2 diabetes mellitus with kidney complications
Registration Number
CTRI/2018/04/013063
Lead Sponsor
Dr Aparna Sathe
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
99
Inclusion Criteria

1. Adult ( >18 yrs) either gender with prior diagnosis of DKD.

2. Known case of Type 2 DM diagnosed at least since 6 months.

3. CKD stage 3

3 a : e GFR (EPI) 45 to < 60

3 b : e GFR (EPI) 30 to < 45

4. Participants on stable and acceptable dose of ACE inhibitors or ARB (angiotensin II receptor blockers)

Exclusion Criteria

1)Type I DM

2)Lack of clinical evidence or suspicion of renal diagnosis other than DKD

3)UACR > 5000mg/g on any major measurement during screening.

4)Uncontrolled Diabetes (HB1Ac > 8%)

5)ESRD receiving dialysis or Anticipated progression to ESRD within treatmentperiod.

6)Status postrenal transplant.

7)Unstable CVD

8)Other concomitant disease that could impair patients safety or ability to participate in study.

9)Known case of Immunocompromised patients or subjects on immunorupressive drugs.

10)Pregnant and lactating females.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
!) Participants showing relief from clinical sign and symptoms. <br/ ><br> <br/ ><br>2)Decrease in ACR <br/ ><br>3)Increase in EGFREPI <br/ ><br>Timepoint: Follow up at Every 30days
Secondary Outcome Measures
NameTimeMethod
Decrease in ACR <br/ ><br>Increase in EGFREPI <br/ ><br>Timepoint: At interval of 3 months <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath